LUPIN.BO - LUPIN LTD.

BSE - BSE Real Time Price. Currency in INR
829.45
+0.15 (+0.02%)
At close: 3:58PM IST
Stock chart is not supported by your current browser
Previous Close829.30
Open835.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range827.00 - 839.50
52 Week Range818.55 - 1,572.25
Volume173,211
Avg. Volume212,881
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped
    Reuters2 days ago

    Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

    (Reuters) - Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday. Drugmakers ...

  • FDA Warns India's Lupin Over Generic Drug Quality Violations
    Bloomberg5 days ago

    FDA Warns India's Lupin Over Generic Drug Quality Violations

    Lupin Ltd., which makes generic antibiotics, antidepressants and heart medications for sale in the U.S., was warned by the Food and Drug Administration for repeatedly ignoring tests showing that pills ...

  • Reuters20 days ago

    Lupin Q2 profit falls on lower U.S. sales, but beats estimates

    REUTERS - Drugmaker Lupin Ltd (LUPN.NS) said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened ...

  • Reuters20 days ago

    India's Lupin Q2 profit falls on lower U.S. sales, but beats estimates

    Indian drugmaker Lupin Ltd said on Monday second-quarter net profit fell more than 30 percent, as regulatory scrutiny and pricing pressure in the United States, its biggest market, dampened sales. The ...

  • Nifty, Sensex end higher; investors eye Sept-quarter results
    Reuterslast month

    Nifty, Sensex end higher; investors eye Sept-quarter results

    REUTERS - Indian shares rose for a third straight session on Tuesday but the gains were capped as investors hedged their bets before September-quarter corporate results kick in later this week. The benchmark ...

  • Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge
    Bloomberg2 months ago

    Cheap Drugs Pay for Aurobindo as U.S. FDA Approvals Surge

    While India’s largest pharmaceutical companies have seen drug approvals in the U.S. slow overall, their research and development spending has been on a run. Not so for Aurobindo Pharma Ltd.Quarter after ...

  • Reuters4 months ago

    India's Lupin Q1 profit slumps, misses estimates

    Indian drugmaker Lupin Ltd said on Wednesday first quarter profit fell 59 percent, well below analysts' estimates, as regulatory hurdles and pricing pressure in the United States, its biggest overseas market, weighed. Lupin, which specialises in oral contraceptives and drugs to treat diabetes and hypertension, said sales in the United States fell about 27 percent to 16.02 billion rupees, while domestic sales were down 1.8 percent at 9.32 billion rupees. Analysts on average expected Lupin to post a profit of 4.79 billion rupees, Thomson Reuters data showed.

  • What You Don't Know About Generic Drugs, and How It Can Hurt You
    Bloomberg5 months ago

    What You Don't Know About Generic Drugs, and How It Can Hurt You

    To keep his anxiety under control, Peter, a 35-year-old government employee, relied for nine years on a blue-and-white pill he popped every night before bed: Cymbalta, made by Eli Lilly & Co. When a generic ...

  • Bloomberg6 months ago

    Lupin Plunges After Warning U.S. Drug Sales May Extend Drop

    Lupin Ltd. fell to its lowest point in almost three years after warning that its U.S. revenue may extend declines over the coming year after India’s second-largest drug maker lost exclusive rights to sell ...

  • Reuters6 months ago

    Indian drugmaker Lupin warns of more pricing pressure as Q4 profit halves

    Indian drugmaker Lupin Ltd expects to launch over 30 products in the United States this year, but warned revenue growth would remain muted due to growing pricing pressure and competition in the world's largest healthcare market. "We've talked about medium single digits of price erosion in the past and I think we are now (seeing) high single digits," Managing Director Nilesh Gupta told Reuters after Lupin reported a quarterly profit that halved from a year earlier. The country's third-largest drugmaker has been working on building a pipeline of high-value complex generic drugs in the United States to offset growing competition in plain generics.

  • Bloomberg8 months ago

    Lupin CFO Says $1 Billion M&A War Chest May Be Just The Start

    Lupin Ltd.’s point man for mergers and acquisitions figures he has about $1 billion to work with as he hunts for targets to hasten the Indian firm’s move from simple generic drugs to more profitable products. ...